BioVal BioStock Analytics initiates coverage of SynAct Pharma

Bitget2026/11/03 14:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioVal BioStock Analytics initiated coverage of SynAct Pharma under a research engagement with the company.
The analysis values resomelagon in rheumatoid arthritis, respiratory viral infections and dengue at SEK 2.9 billion (USD 295 million).
The combined valuation reflects risk-adjusted net present values, with most assigned to rheumatoid arthritis.
An FDA Type C meeting request addresses a potential pivotal Phase 3 design; feedback is expected by early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioVal BioStock Analytics initiates coverage of SynAct Pharma

You may also like

Crypto prices